Stentys

stentys is developing and commercializing innovative solutions for the treatment of patients with complex artery disease. stentys’ selfapposing® drug-eluting stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. the apposition clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents. the company’s product portfolio also includes mistent ses®, a coronary des whose new drug delivery mechanism is designed to match vessel response, and is marketed through stentys’ commercial network in europe, the middle east, asia and latin america.